Nucleic acids encoding anti-IL-12 antibody

Patent metadata

Field	Value
Publication number	US-9605067-B2
Application number	US-201615217099-A
Country	US
Kind code	B2
Filing date	Jul 22, 2016
Priority date	Aug 7, 2000
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

First claim

What is claimed is:

1. An isolated nucleic acid molecule encoding a mammalian anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9.

2. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule according to claim 1 .

3. An isolated prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claim 1 .

4. The host cell according to claim 3 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells.

5. A method for producing an anti-IL-12 antibody, comprising translating the nucleic acid molecule according to claim 1 under conditions in vitro, such that the IL-12 antibody is expressed in detectable or recoverable amounts.

6. An isolated nucleic acid molecule encoding a mammalian anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 23, 40, 43, 45, 59 and 62 of the amino acid sequence of SEQ ID NO:9.

7. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule according to claim 6 .

8. An isolated prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claim 6 .

9. The host cell according to claim 8 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells.

10. A method for producing an anti-IL-12 antibody, comprising translating the nucleic acid molecule according to claim 6 under conditions in vitro, such that the IL-12 antibody is expressed in detectable or recoverable amounts.

Assignees

• Janssen Biotech Inc

Inventors

• Giles-Komar Jill
• Heavner George
• Knight David
• Luo Jinquan
• Peritt David
• Scallon Bernard
• Shealy David

Classifications

• A61P7/06

  Antianaemics · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/02

  Immunomodulators · CPC title